NCT00660842

Study Comparing Weekly Versus Every 3 Week Chemotherapy in Patients With Ovarian Cancer

Weekly Versus Every 3 Week Carboplatin and Paclitaxel in Patients With Ovarian Cancer: a Phase III Randomized Multicenter Study

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 800 (estimated)
• Sponsor: National Cancer Institute, Naples · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to study efficacy and the effects on quality of life in women with ovarian cancer treated with a weekly schedule of chemotherapy with carboplatin and paclitaxel compared to those treated with standard every 3 weeks schedule of the same chemotherapy.

Detailed description

The standard first-line treatment of ovarian cancer is combination chemotherapy with carboplatin and paclitaxel, given every 3 weeks. Researchers are looking at new ways of giving chemotherapy to make it more tolerable and more effective. One way is by giving the chemotherapy more often in smaller doses. This approach can be associated with fewer or less troubling side effects. Some chemotherapy drugs such as paclitaxel have been shown to also be more active when given once a week rather than once every 3 week schedule.

Conditions

• Ovarian Cancer

Interventions

Type	Name	Description
PROCEDURE	carboplatin	AUC 6 IV day 1 every 21 days
DRUG	paclitaxel	175 mg/m2 IV day 1 every 21 days
DRUG	carboplatin	AUC 2 IV every week
DRUG	paclitaxel	60mg/m2 IV every week

Timeline

• Start date: 2008-11-01
• Primary completion: 2024-11-01
• Completion: 2024-11-01
• First posted: 2008-04-17
• Last updated: 2023-03-24

Locations

28 sites across 1 country: Italy